Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Inhibikase Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Inhibikase Therapeutics, Inc.

IKT

Inhibikase Therapeutics, Inc.

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics is a clinical-stage biotech focused on developing therapeutics for cardiopulmonary and neurological diseases. Its pipeline includes IKT-001, a prodrug of imatinib for pulmonary arterial hypertension, and risvodetinib for Parkinson’s disease. The company leverages proprietary kinase inhibitor technology, seeks FDA approval via the 505(b)(2) pathway, and collaborates with research institutions, aiming to offer disease-modifying treatments in niche markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Inhibikase Therapeutics, Inc.

1
1
Inhibikase Therapeutics, Inc. Inhibikase Therapeutics Reports $16.4 Million Net Loss in Q1 2026, Increases Clinical Development Efforts

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Inhibikase Therapeutics, Inc. Inhibikase Therapeutics Reports $48.3 Million Net Loss and Advances Phase 3 Study for IKT-001

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Inhibikase Therapeutics, Inc. Inhibikase Therapeutics Reports $11.9 Million Net Loss for Q3 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Inhibikase Therapeutics, Inc. Inhibikase Therapeutics Reports $9.9 Million Net Loss and Strategic Developments in Latest 10-Q Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Inhibikase Therapeutics, Inc. Inhibikase Therapeutics Reports $13.7 Million Net Loss and Increased R&D Expenses in Latest 10-Q

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Inhibikase Therapeutics, Inc. Inhibikase Therapeutics Reports $27.5 Million Net Loss for 2024, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Inhibikase Therapeutics, Inc. Inhibikase Therapeutics Reports Significant Financial Challenges, Raises $110M in Private Placement

Via official filing (AI summary) | over 1 year ago | 0 comments